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11 Abstract
12 Purpose of Review We highlight new entities of congenital
13 diarrheal disorders (CDDs) and progresses in understanding
14 of functionally related genes, opening new diagnostic and
15 therapeutic perspectives.
16 Recent Findings The more significant advances have been
17 made in field of pathogenesis, encouraging a better under-
18 standing not only of these rare diseases but also of more com-
19 mon pathogenetic mechanisms.
20 Summary CDDs represent an evolving group of rare chronic
21 enteropathies with a typical onset early in the life. Usually,
22 severe chronic diarrhea is the main clinical manifestation,
23 but in other cases, diarrhea is only a component of a more
24 complex systemic disease. The number of conditions has
25 gradually increased, and many new genes have been
26 indentified and functionally related to CDDs, opening new
27diagnostic and therapeutic perspectives. Advances in molecu-
28lar analysis procedures have modified the diagnostic approach
29in CDDs, leading to a reduction in invasive and expensive
30procedures.
31Keywords Chronic diarrhea . Genes .Molecular analysis .
32Mutations . Children
33Introduction Q1=Q2
34Congenital diarrheal disorders (CDDs) are a group of rare
35hereditary enteropathies, characterized by a typical onset dur-
36ing the first days of life [1••]. Although, most of these diseases
37present similar clinical features, the causes, the management,
38and prognosis of various forms of CDDs are very different.
39For most of these conditions, a severe chronic diarrhea is the
40primary clinical manifestation; more rarely, diarrhea is only
41one component of a multiorganmore complex picture. Inmost
42cases, an appropriate therapy should be initiated immediately
43in order to prevent dehydration and serious short- and long-
44term complications [1••]. There are also milder forms of
45CDDs, with a less severe clinical picture, diagnosed in later
46ages, typically due to mutations that less severely impair the
47residual activity of the disease-protein. To date, genes respon-
48sible for disease are known in most cases of CDDs. Therefore,
49molecular analysis has assumed a key role in the diagnostic
50approach to a patient suspected of CDDs and, in some cases,
51in the prediction of the outcome of the disease (genotype–
52phenotype correlation). Evolving knowledge of the pathogen-
53esis of CDDs suggests the utility of a classification system
54based on the main pathogenetic mechanism, which could help
55the approach to these patients (Fig. 1). This classification com-
56prises four groups of disorders:
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57 I. Defects in digestion and absorption of nutrients and
58 electrolytes
59 II. Defects in enterocyte structure
60 III. Defects in enteroendocrine cell differentiation
61 IV. Defects in intestinal immune-related homeostasis.
62
63 We review new CDD entities and advances understanding
64 of functionally related genes that are opening new diagnostic
65 and therapeutic perspectives, underlining the crucial role of
66 molecular analysis.
67 Defects in Absorption and Transport of Nutrients
68 and Electrolytes
69 Most of the CDDs belong to this group. These diseases derive
70 from a defect in one of the main mechanisms of digestion or
71 transport that leads to severe diarrhea and subsequent dehy-
72 dration and weight loss early after birth. Specifically, the de-
73 fect can be charged to brush border membrane, membrane
74 carriers, pancreatic enzymes, lipid transport and metabolism,
75 ribosomal proteins, and mitochondrial DNA [2••] (Table 1).
76 The alteration of digestion or absorption of carbohydrates,
77 proteins, and electrolytes results in osmotic diarrhea. Fecal
78 pH <5, ion gap >50, and molecular analysis confirm the diag-
79 nosis. The prototypes of this group are glucose–galactose mal-
80 absorption and congenital chloride diarrhea [1••], but new
81conditions have been described. No histological or ultrastruc-
82tural defects are generally observed in these patients at gut
83level [1••].
84Familial Diarrhea Syndrome
85Main Clinical Features This condition has been described in
8632 members of a Norwegian family, and is characterized by
87early-onset chronic diarrhea and meteorism. In a subset of
88patients, abdominal pain and dysmotility have been described
89as main features [4•]. Patients have an increased risk to devel-
90op Crohn’s disease and intestinal obstruction resulting from
91volvulus, adhesional bands, and/or ileal inflammation [5].
92Genotype All affected members have an activating heterozy-
93gous missense mutation (p.Ser840Ile) in the GUCY2C gene,
94which encodes for the intestinal guanylate cyclase receptor for
95uroguanylin, guanylin, and heat-stable enterotoxins [4•].
96Activation of the guanylate Q4cyclase C (GC-C) receptor in-
97creases cellular levels of cyclic guanosine monophosphate
98(cGMP), leading to phosphorylation of the cystic fibrosis
99transmembrane conductance regulator (CFTR) channel [5].
100The efflux of Cl− and water into the intestinal lumen, with
101reduced sodium ion (Na+) absorption owing to inhibition of
102the Na+–H+ exchanger 3 (NHE3) [5], leads to a severe chronic
103secretory diarrhea. GC-C signaling also has implications for
104renal electrolyte homeostasis, intestinal cell proliferation, ap-
105optosis, intestinal barrier function, and inflammation [5].
Enteroendocrine cell
Stem cell
Paneth cell
Immune cells
Nutrients and electrolytes
Defects in digestion and absorption of nutrients
and electrolytes: chronic osmotic diarrhea derives
from defects in ion and solutes transporters or 
enzimatic activities
Defects in enterocytes structure: 
cytoscheleton dysregulation leading to 
alterations in enterocytes structure and 
function with chronic diarrhea
Defects in enteroendocrine cell
differention: defects in stem cells
differentiation process lead to 
enteroendocrine cell dysgenesis with 
chronic osmotic diarrhea
Defects in intestinal immune-related homeostasis: chronic
secretory diarrhea drived by inflammation and mucosal
damage deriving from immune dysregulation
Fig. 1 The improving knowledge about the pathogenesis of congenital diarrheal disorders has inspired a new classification that could help the diagnostic
and therapeutic approach to these conditions
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t1:1 Table 1 MainQ3 features of congenital diarrheal disorders: genetics and epidemiology
t1:2 Disease Gene Protein Inheritance and incidence
t1:3 Name OMIM
number
Position
t1:4 Defects in absorption and ransport of nutrients and electrolytes
t1:5 Congenital chloride
diarrhea
SLC26A3 126650 7q31.1 Cl−/base exchanger AR, sporadic; common in
some ethnic groups
t1:6 Congenital sodium
diarrheaa
SLC29A3 182307 5p15.33 Na+–H+ exchanger AR, <1:1,000,000
t1:7 Congenital lactase
deficiency
LCT 603202 2q21.3 Lactase–phlorizin
hydrolase
AR, 1:60,000 in Finland;
lower in other ethnic
groups
t1:8 Sucrase–isomaltase
deficiency
SI 609845 3q26.1 Isomaltase–sucrase AR, 1:5000; higher in
Greenland, Alaska,
and Canada
t1:9 Maltase–glucoamylase
deficiency
MGAM 154360 7q34 Maltase–glucoamylase Only few cases described
t1:10 Glucose–galactose
malabsorption
SLC5A1 182380 22q13.1 Na+/glucose
cotransporter
AR, a few hundred
cases described
t1:11 Fanconi–Bickel
syndrome
SLC2A2 138160 3q26.2 Basolateral glucose
transporter
AR, rare
t1:12 Acrodermatitis
enteropathica
SLC39A4 607059 8q24.3 Zn2+ transporter AR, 1:500.000
t1:13 Lysinuric protein
intolerance
SLC7A7 603593 14q11.2 Cationic amino acid
transporter
AR, approximately
1:60,000 in Finland
and Japan; rare in
other ethnic groups
t1:14 Primary bile acid
diarrhea
SLC10A2 601295 13q33.1 Ileal Na+/bile salt
transporter
AR
t1:15 FGF-19 603891 11q13.3 Bile acids negative
feedback
Only few cases described
t1:16 Enterokinase
deficiency
TMPRSS15 606635 21q21.1 Proenterokinase AR
t1:17 Abetalipoproteinemia MTTP 157147 4q23 Microsomal triglyceride
transfer protein
AR, about 100 cases
described; higher
frequency among
Ashkenazi
t1:18 Hypobetalipoproteinemia Apo B 107730 2p24.1 Apolipoprotein B
100/48
Autosomal codominant
t1:19 Chylomicron retention
disease
SAR1B 607690 5q31.1 Intracellular
chylomicron
trafficking
AR, about 40 cases
described
t1:20 Familial diarrhea
syndrome
GUCY2C 601330 12p13.1-p12.3 Receptor for heat-stable
enterotoxins
Described in 32 members
of a Norwegian family
t1:21 Diarrhea-associated
DGAT1 mutation
DGAT1 604900 8q24.3 Diacylglycerol
acyltransferases
One family has been
reported
t1:22 Defects in enterocyte
structure
t1:23 Microvillous inclusion
disease
MYO5B 606540 18q21.1 Myosin VB AR; rare; highest
frequency mong
Navajo
t1:24 STX3 600876 11q12.1 Syntaxin3 AR; two patients
described
t1:25 Congenital tufting
enteropathyb
EPCAM 185535 2p21 Protein for cell–cell
interaction
AR; 1:50–100.000; higher
among Arabians
t1:26 SPINT2 605124 19q13.2 Serine protease inhibitor <1/1,000,000
t1:27 Trichohepatoenteric syndrome
(syndromic diarrhea)
TTC37 614589 5q15 Component of the SKI
complex
AR; <1/1,000,000
t1:28 SKIV2L 600478 6p21.33 Helicase AR; <1/1,000,000
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106 Treatment Total parenteral nutrition is the only therapeutic
107 option at the moment [4•, 5].
108 DGAT1-Deficiency-Related Diarrhea
109 MainClinical Features Protein-losing enteropathy (PLE) is a
110 clinical disorder of protein loss from the gastrointestinal sys-
111 tem that results in hypoproteinemia and malnutrition.
112 Genotype Patients with mutations in DGAT1 (which encodes
113 acyl CoA/diacylglycerol acyltransferases 1) present aspects of
114 both PLE and CDD [6]. DGATs catalyze the final step of
115 triglyceride synthesis. Animal models lacking DGAT1 show
116 delayed fat absorption with more fat reaching the distal gut.
117 However, how DGAT1 deficiency causes diarrhea and protein
118 losing enteropathy is still unknown, but it is possible that
119 excess diacylglycerols or fatty acids could have a toxic role,
120maybe acting as bioactive signaling lipids or via a detergent-
121like action [7•]. Several differences, however, are apparent
122among the reported cases and regard the serum lipid profile,
123including triglycerides, the presence of digital clubbing and
124the onset of diarrhea. These phenotypic differences may re-
125flect genotypic differences [7•].
126Treatment Total parenteral nutrition is the only therapeutic
127option at the moment [7•].
128Defects in Enterocyte Structure
129This group of CDDs includes microvillus inclusion disease
130(MVID), congenital tufting enteropathy (CTE), more recently
131trichohepatoenteric syndrome (THE) has added to the group
132(Table 1). During the last years, mutations in genes, involved
t1:29 Table 1 (continued)
Disease Gene Protein Inheritance and incidence
t1:30 Name OMIM
number
Position
t1:31 Defects in enteroendocrine
cell differentiation
t1:32 Enteric anendocrinosis NEUROG3 604882 10q22.1 Transcriptional
regulator
AR; few cases described
t1:33 X-linked lissencephaly
and MR
ARX 300382 Xp21.3 Homeodomain
transcription factors
X-linked
t1:34 Proprotein convertase
1/3 deficiency
PCSK1 162150 5q15 Neuroendocrine
convertase
AR; <1/1,000,000
t1:35 Mitchell–Riley Syndrome RFX6 612659 6q22.1 Transcription factors AR
t1:36 Defects in intestinal immune-related
homeostasis
t1:37 Immunodysregulation,
polyendocrinopathy,
enteropathy,
X-linked syndrome
FOXP3 300292 Xp11.23 Transcription factor X-linked
t1:38 IPEX-like disorders CD25 147730 10p15.1 Interleukin-2 receptor,
alpha chain
AR
t1:39 STAT5b 604260 17q21.2 Transcriptional regulator AR
t1:40 STAT-1 600555 2q32.2 Transcriptional regulator AD, loss/gain of function
t1:41 ITCH 606409 20q11.22 Ubiquitin protein ligase AR (one family)
t1:42 LRBA 606453 4q31.3 Protein involving in
apoptosis
AR, three family described
t1:43 MALT-1 604860 18q21.32 Protein involving in
NF-κB activation
AR (one family)
t1:44 Early onset enteropathy
with colitis
IL-10
IL-10Rα
IL-10Rβ
124092
146933
123889
1q32.1
11q23.3
21q23.3
Cytokine or cytokine
receptors
AR
aAnalysis of the intestinal brush border membrane of affected patients revealed that the condition is caused by a SLC9A3 loss-of-function mutations.
SLC9A3 encodes Na+ /H+ antiporter 3 (NHE3), the major intestinal brush border Na+ /H+ exchanger. A syndromic form of CSD is characterized by the
presence of choanal and intestinal atresias as well as recurrent corneal erosions. Small bowel histology frequently detects an epithelial “tufting” dysplasia.
It is autosomal recessively inherited and associated to SPINT2 mutations [3]
b Congenital tufting enteropathy associated to EPCAM mutation is characterized by only intestinal involvement, while mutation in SPINT2 leads to a
syndromic form with dysmorphic features, wooly hair, small birth weight and immune deficiency, and diarrhea with high sodium content in the stools
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133 in intestinal epithelial physiology, have been associated with
134 different CDDs, opening new perspectives in understanding
135 the pathogenetic mechanism and in the clinical approach [1••].
136 Parenteral nutrition and intestinal transplantation are the only
137 therapeutic strategies available at the moment; they have re-
138 duced the morbility and mortality rates of these diseases [1••].
139 Microvillus Inclusion Disease
140 Main Clinical Features Loss of apical microvilli and forma-
141 tion of microvillus inclusion in the cytoplasm of enterocytes
142 are the main hallmarks ofMVID [8•]. These alterations lead to
143 persistent diarrhea, nutrient malabsorption, and failure to
144 thrive. In most cases (95%), symptoms develop within days
145 after birth, but there is a late-onset variant, which presents 2–
146 3 months postnatally. Extra intestinal symptoms could be
147 intrahepatic cholestasis and renal Fanconi syndrome. Some
148 individuals with MVID present less-severe digestive symp-
149 toms for reasons that are not clear [9••]. Intestinal biopsy is
150 the most important method to diagnose this disease. This will
151 display: features of villus atrophy, microvillus atrophy, and the
152 redistribution of CD10 and periodic acid Schiff (PAS)-stained
153 material from the brush border to intracellular sites in the
154 enterocytes. A definitive diagnosis includes analysis by elec-
155 tron microscopy (EM) for microvillus inclusions in the cyto-
156 plasm of enterocytes. It is interesting that microvillus inclu-
157 sions are also present in rectal biopsies, facilitating diagnosis
158 if a duodenal biopsy is not available [9••].
159 Genotype Loss of function mutations in the actin motor my-
160 osin Vb (MYO5B) is responsible for most cases of MVID.
161 Recently, mutations in the SNARE fusion protein syntaxin 3
162 (STX3) and STXBP2 were reported in the milder MVID var-
163 iant [10]. MYO5B encodes the actin-based motor protein my-
164 osin Vb, which consists of an N-terminal actin binding motor
165 domain and a C-terminal tail domain that includes the
166 cargobinding domain. The myosin Vb cargobinding domain
167 binds selectively to small Rab GTPases, among which
168 RAB11A and RAB8A. MYO5b, in concert with RAB11A
169 and RAB8A associated with apical recycling endosomes
170 (AREs), in polarized epithelial cells controls the activity of
171 the small GTPase CDC42, and it modulates intestinal epithe-
172 lial cells polarity, apical trafficking, and microvilli growth
173 [10]. At the basis of MVID’s pathogenesis, it was demonstrat-
174 ed an uncoupling of myosin Vb from RAB11A and RAB8A,
175 caused from the mutation of myosin Vb. Two other mutations
176 involved in MVID interested STX, which encodes the trans-
177 membrane protein syntaxin-3, or STXBP2, which encodes
178 Munc18-2 [11]. In enterocytes, syntaxin-3 is localized at the
179 apical cell-surface domain, where it, in concert with SNAP23
180 and Munc18-2, has the function of mediating the fusion of
181 transport vesicles with the apical plasma membrane. The mu-
182 tation STX3, responsible for MVID, leads to depletion of the
183syntaxin-3 or the expression of a syntaxin-3 protein that lacks
184its transmembrane domain, with the loss of its function.
185STXBP2 mutations abolish the interaction of Munc18-2 with
186syntaxin proteins [11].
187THE
188Main Clinical Features Trichohepatoenteric syndrome, also
189called syndromic diarrhea, is a rare life-limiting autosomal
190recessive bowel disorder [12]. Main symptoms are chronic
191diarrhea, facial dysmorphism, trichothiodystrophy associated
192or not with liver disease, hepatomegaly, siderosis, congenital
193cardiac defects, and platelet anomalies [12]. Affected people
194are susceptible to infection, because they might fail to produce
195antibodies upon vaccination, or present with low immuno-
196globulin levels. In 50% of all cases, it is possible to find mild
197intellectual deficiency. Clinical dates and via biopsies of the
198small intestine are useful to make diagnosis. The biopsies
199display the typical histological and ultrastuctural defects: vil-
200lus atrophy and variable immune cell infiltration of the thin
201layer of loose connective tissue that lies beneath the epitheli-
202um [12].
203Genotype Recent studies have shown that the mutations in-
204volved in this disease are associated with TTC37 or SKIV2L
205[13]. The gene’s products of both TTC37 and SKIV2L are
206human homologs of components of the yeast Ski complex,
207which is linked with exosome-mediated degradation of aber-
208rant messenger RNA Q5(mRNA) and associated with transcrip-
209tionally active genes. TTC37 (also called Thespin) encodes
210the tetratricopeptide repeat protein 37 and it is expressed in
211many tissues like vascular endothelium, lung and intestine,
212but not in the liver. In enterocytes with TTC37 mutations,
213the brush-border-associated NHE-2 and NHE-3, aquaporin
2147, the Na+/I− symporter, and the H+/K+-ATPase show reduced
215expression or mislocalization to the apical cytoplasm, with
216different patterns of mislocalization relative to their normal
217pattern [12]. In conclusion, the loss of TTC37 results in the
218defective trafficking and/or decreased expression of apical
219transport proteins, including aquaporin 7.
220The other mutation identified in the THE regard SKIV2L,
221which encodes SKI2 homolog, superkiller viralicidic activity
2222-like protein, which might be involved in antiviral activity by
223blocking translation of poly (A)-deficient mRNAs. The mech-
224anism, which is the base of the disease, is associated with loss
225of function a cytoplasmic-exosome cofactor involved in vari-
226ous mRNA decay pathways and required for normal cell
227growth [12].
228Congenital Tufting Enteropathy
229Main Clinical Features Typical is the presence of epithelial
230tufts that can be localized from the duodenum to the large
Curr Pediatr Rep
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231 intestine [1••]. Patients affected by this condition have persis-
232 tent diarrhea that presents immediately or just after birth, de-
233 spite bowel rest, and total parenteral nutrition.
234 A subset of individuals with CTE displays a syndromic
235 form of the disease that includes other signs and symptoms
236 like dysmorphic features, wooly hair, punctate keratitis, atre-
237 sias, reduced body size, and immune deficiency [14].
238 Histological features of CTE reveal various degrees of villus
239 atrophy, basement membrane abnormalities, disorganization
240 of enterocytes and focal crowding at the villus tips, resembling
241 tufts.
242 Genotype In CTE, the absence of epithelial cell adhesion
243 molecule (EPCAM) in enterocytes is considered the most
244 important diagnostic marker [15•]. EPCAM, expressed
245 along the basolateral membranes, is a multifunctional
246 transmembrane glycoprotein, and it has an important role
247 in cell–cell adhesion, proliferation, and differentiation. In
248 this disease, EPCAM protein levels in the intestine are
249 decreased and all CTE-associated EPCAM mutations lead
250 to loss of cell-surface EPCAM, either because of impaired
251 plasma membrane targeting or because of truncation of
252 the protein, both of which result in its secretion [15•].
253 Recent studies have demonstrated that in the EPCAM
254 KO mouse intestine, E-cadherin, and beta-catenin, two
255 adherens junction-associated proteins are also mislocal-
256 ized, leading to disorganized transition from crypts to villi
257 [15•]. Recently, it has been demonstrated that a second
258 group of CTE individuals is characterized by mutations
259 in SPINT2 [14]. SPINT2 encodes the transmembrane pro-
260 tein Kunitz-type 2 serine-protease inhibitor which is in-
261 volved in epithelial regeneration, in the Nf-Kb and TGF-
262 beta signaling pathways. The inhibition of trypsin-family
263 serine peptidases, which are encoded by SPINT2, abol-
264 ishes the stimulation of apical Na+ transport by
265 nonvoltage-gated sodium channel-1-alpha (SCNN1A) in
266 polarized intestinal epithelial cells, which could contribute
267 to secretory diarrhea. It is possible that such a mechanism
268 is the basis of the syndromic form of congenital sodium
269 diarrhea that is associated with SPINT2 mutations [14].
270 Defects in Enteroendocrine Cell Differentiation
271 Abnormal enteroendocrine cell development or function and
272 congenital malabsorptive diarrhea, associated or not with oth-
273 er systemic endocrine abnormalities, are the main features of
274 this group of extremely rare forms of CDDs. Various null
275 mouse models of each of these genes are associated with early
276 postnatal mortality and occasionally diarrhea [1••]. Genes in-
277 volved in this group are as follows: neurogenin-3
278 (NEUROG3), regulatory factor X-6 (RFX6), aristaless-
279 related homeobox (ARX), and proprotein convertase
280subtilisin/kexin type 1 (PCSK1) (Table 1). Parenteral nutrition
281and intestinal transplant are the only two therapeutic options
282in these patients [1••, 16–19].
283Enteric Anendocrinosis and Mitchell–Riley Syndrome
284Main Clinical Features and Genotype NEUROG3 controls
285the fate of enteric cells in both the pancreas and the intestine.
286Biallelic mutations in NEUROG3 are known to cause a rare
287but well-defined clinical syndrome characterized by severe
288malabsorptive diarrhea from early life and mild nonketotic
289diabetes with a variable age of onset [16–18]. Few reports
290suggest that NEUROG3 may influence pancreatic exocrine
291function, possibly through its activation of NEUROD1 [20].
292Homozygous mutations of RFX6 are associated with a com-
293plex clinical phenotype characterized by duodenal atresia, bil-
294iary abnormalities, neonatal diabetes mellitus, and
295malabsorptive diarrhea (Mitchell–Riley Syndrome) [20].
296RFX6 is a winged helix transcription factor that is down-
297stream of NEUROG3, and it is required for islet cell develop-
298ment and for enteroendocrine cells function [21•]. Mutation of
299RFX6 is associated with normal enteroendocrine cells num-
300ber. The intestinal atresia associated with RFX6 mutations is
301probably related to a not yet fully characterized role in early
302gut endoderm. Furthermore, while murine studies suggest that
303RFX6 is exclusively expressed in enteroendocrine K-cells that
304express gastric inhibitory polypeptide and others hormones, it
305remains uncertain if this subset of cells are depleted in humans
306with RFX6 deficiency [22].
307Other Defects of Enteroendocrine Cell Differentiation
308Main Clinical Fetures and Genotype A complex clinical
309phenotype of X-linked mental retardation, seizures,
310lissencephaly, abnormal genitalia, and occasionally congenital
311diarrhea is due to mutations in the ARX gene (a prd-
312homeodomain transcription factor) [23, 24]. The ARX gene
313is a down-stream target of NEUROG3 and is expressed in a
314subgroup of enteroendocrine cells including those that express
315CCK, secretin, and glucagon [25]. More than 50% of patients
316described with loss-of-function ARX mutations present a
317polyalanine expansion that may be responsible for the highly
318variable neurologic and intestinal clinical phenotypes associ-
319ated with this condition [26]. All active hormones produced
320by endocrine cells are processed by a specific Ca2+-dependent
321serine endoprotease named prohormone convertase 1/3 (PC1/
3223). Homozygote loss-of-function mutations in PCSK1 gene
323encoding for PC1/3 have been associated with malabsorptive
324diarrhea and other endocrinopathies, including adrenal insuf-
325ficiency, hypothyroidism, and hypogonadism [27]. PCSK1 is
326also expressed at hypothalamic level, producing various cen-
327tral orexigenic hormones that control appetite. Children pre-
328senting mutations of PCSK1 are extremely polyphagic [28].
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329 In a cohort of children with this disorder (enteric
330 dysendocrinosis) was found severe failure to thrive, and PN
331 was required for the first several years of life [28]. These
332 children also develop diabetes insipidus and growth hormone
333 deficiency that distinguish PCSK1 deficiency from other en-
334 teric endocrinopathies. These findings suggest that enteric
335 hormones may be particularly important to facilitate nutrient
336 absorption during infancy when caloric requirement (per body
337 weight) is at its highest [29].
338 Defects in Intestinal Immune-Related Homeostasis
339 IPEX Syndrome
340 Main Cl inical Features Immunodysregula t ionQ6 ,
341 polyendocrinopathy, enteropathy, X-Linked (IPEX) syndrome
342 is a monogenic autoimmune disease with early life onset that
343 is considered the prototype of the defects in intestinal
344 immune-related homeostasis. This rare syndrome is character-
345 ized by multiorgan autoimmunity, including severe diarrhea
346 due to autoimmune enteropathy, chronic dermatitis, and
347 endocrinopathy (type 1 diabetes mellitus, hypothyroidism).
348 In more severe cases, symptoms onset starts in the immediate
349 fetal period with hydrops [30]. In addition to the intestinal
350 architectural changes due to dysregulation of Treg cells activ-
351 ity, patients with IPEX syndrome present serum autoanti-
352 bodies to enterocyte antigens harmonin and villin that are
353 uniquely found in IPEX and have high diagnostic value [31,
354 32]. IPEX syndrome is often fatal early in infancy; therefore, a
355 prompt diagnosis is essential to start treatment as soon as
356 possible, before tissue damage spreads to multiple organs
357 [33].
358 Genotype IPEX is caused by loss of function mutations in the
359 gene encoding the forkhead box P3 (FOXP3) on X-
360 chromosome (Xp11.23) transcription factor for thymic-
361 derived CD4+CD25+ regulatory T (Treg) cell (Table 1).
362 These cells play a key role in the establishment and mainte-
363 nance of immune tolerance [34]. Recently, a novel mutation in
364 the FOXP3 gene is identified at Phe367 residue level. Phe367
365 is a key structural residue of the DNA-binding domain of
366 FOXP because of its contribution to the dimeric state of
367 FOXP3, and this mutation may have a disruptive effect on
368 the interaction network whose integrity is essential for
369 FOXP3 regulatory activity [34]. As a consequence,
370 FOXP3mut Tregs normally differentiate in the thymus and
371 can be detected in the peripheral blood and tissues of IPEX
372 patients, but they are unable to suppress Teff cells. The early
373 neonatal onset and severity of IPEX enteropathy suggests that
374 likely the damage is established even during fetal life, inde-
375 pendently from external environmental factors, such as nutri-
376 ents and gut microbiota.Whole exome sequencing identified a
377novel nonsense mutation in the FOXP3 gene, c.1009C>T,
378which was inherited from the mother. FOXP3 is also transient-
379ly expressed by any activated T cells, in which it controls cell
380cycle and Th development [35••]. Functional data demonstrate
381that Treg cells isolated from IPEX patients are dysfunctional,
382as they cannot inhibit proliferation and cytokine production
383[33]. Indeed, IPEX patients manifest lymphoproliferation,
384skewing towards Th2 and increased frequency of peripheral
385IL-17 producing T cells, frequently found in autoimmune dis-
386eases. The increase in both Th2 and Th17 cells is involved in
387the pathogenesis of the disease and in tissues damage at dif-
388ferent target organ levels. In addition to FOXP3 Treg cells,
389type 1 regulatory T (Tr1) cells represent nonthymic-derived
390Treg cells, able to provide immunoregulation. Tr1 cells main-
391tain their function independently of FOXP3. In IPEX patients,
392the rapid development of immune disease after birth indicates
393that Tr1 cells are not sufficient by themselves to control auto-
394immunity [35••]. Lentiviral-mediated overexpression of wild-
395type FOXP3 successfully conveys stable regulatory function
396to FOXP3mut T cells, opening new therapeutic perspectives
397for IPEX patients [36].
398IPEX-Like Syndromes
399Main Clinical Features This group of CDDs includes an
400expanding spectrum of genetic defects that compromise T
401regulatory cell function that underlies human disorders of im-
402mune dysregulation and autoimmunity. Collectively, these
403disorders offer novel insights into pathways of peripheral tol-
404erance and their disruption in autoimmunity. However, auto-
405immune symptoms phenotypically resembling IPEX often oc-
406cur in the absence of detectable FOXP3 mutations; in fact,
407patients with clinical manifestations of IPEX have a normal
408Foxp3 gene. IPEX-like forms of autoimmune enteropathy
409manifestations have been associated with mutations in genes
410that are important for Treg maintenance, signaling, and expan-
411sion (Table 1) [37].
412Genotype A number of other gene defects that affect T
413regulatory cell function also give rise to IPEX-related
414phenotypes, including loss-of-function mutations in
415CD25, STAT5b, and ITCH. Recent progress includes the
416identification of gain-of-function mutations in STAT1 as a
417cause of an IPEX-like disease, emerging FOXP3geno-
418type/phenotype relationships in IPEX [38–41].The major-
419ity of IPEX-like patients, however, still lack a clear diag-
420nosis. Mutations in the IL-2receptor alpha subunit (CD25)
421are responsible for early-onset enteropathy manifesting
422with severe diarrhea. These patients are more susceptible
423to early infections, like CMV infection. Probably, CD25 is
424essential not only for the Treg cells function but also to
425mount an appropriate immune response, concomitant with
426the immune-dysregulation. It is described that a patient
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427 with clinical manifestations of IPEX had a normal Foxp3
428 gene, but who had CD25 deficiency due to autosomal
429 recessive mutations in this gene. This patient exhibited
430 defective IL-10 expression from CD4 lymphocytes,
431 whereas a Foxp3-deficient patient expressed normal levels
432 of IL-10. These data show that CD25 deficiency results in
433 an IPEX-like syndrome and suggests that although Foxp3
434 is not required for normal IL-10 expression by human
435 CD4 lymphocytes, CD25 expression is important [38].
436 Mutations in STAT5b, responsible for transactivation of
437 the IL-2 signal from CD25 to FOXP3, have been de-
438 scribed associated with reduced Treg cell number [37].
439 Children with STAT5b mutation have symptoms other than
440 enteropathy that can help in establishing the diagnosis. Early-
441 onset chronic/recurrent enteropathy is described in patients
442 with either loss- or gain-of-function mutations in STAT1,
443 which also impinges effective immunity [39]. Some patients
444 with IPEX-like disorder, profound Treg cell deficiency, and a
445 normal FOXP3 gene sequence were found to have a homozy-
446 gous nonsense mutation in the LPS-responsive beige-like an-
447 chor (LRBA) gene, which was previously implicated as a
448 cause of autoimmunity. In fact, some patients with LRBA
449 deficiency manifest increased levels of autoantibodies against
450 autologous antigens in association with a dramatic decreased
451 numbers of circulating Treg cells [39]. The clinical features
452 observed in patients with LRBA deficiency are heterogeneous
453 with the age of presentation ranging from 2 months to
454 12 years. The most common features of the patients are chron-
455 ic diarrhea, organomegaly, respiratory tract infections, and
456 hypogammaglobulinemia [40]. Infections and progressive
457 loss of T cells number and function, including Treg cells, is
458 reported in patients with loss-of-function mutations, whereas
459 Treg instability has been suggested as consequence of the
460 gain-of-function variants, which is characterized by chronic
461 mucocutaneous candidiasis [37]. Another mutation associated
462 with inflammatory unbalance has been described in an extend-
463 ed family with recurrence of lymphoproliferation, inflamma-
464 tion, and dysmorphisms; this concerns ITCH gene, encoding a
465 ubiquitin ligase implicated in several T-cell functions [37].
466 Whole exome sequencing performed in two affected children
467 and their parents, have identified a homozygous missense mu-
468 tation in MALT1 gene (mucosa associated lymphoid tissue
469 lymphoma translocation 1), which inhibits protein expression
470 [42]. NF-κB-dependent lymphocyte activation was resulted
471 severely impaired and there was a drastic reduction in
472 FOXP3 Treg accounting for the IPEX-like phenotype.
473 Following identification of the mutation, both children re-
474 ceived hematopoietic stem cell transplantation, which permit-
475 ted full clinical recovery. Immunological controls at 6 and
476 12 months after transplantation showed normal NF-κB acti-
477 vation and correction of Treg frequency [42]. Mutation in IL-
478 10 receptor alpha and beta is observed in patients with colitis
479 early in life typically associated with skin perianal ulcers and
480strong local inflammation. This condition underlines the
481antiinflammatory action of IL10 and possibly peripheral de-
482velopment of Tr1 cells [41]. Fistula and abscesses can also be
483present, with recurrence, requiring multiple surgical interven-
484tions. Gene mutations in either the alpha or beta subunit of the
485IL-10 receptor (IL-10R1 and 2) abrogate response to IL-10,
486and this causes persistent colonic inflammation [41].
487Currently, the most effective therapy to cure the disease is
488hematopoietic stem cell transplantation [41]. Although studies
489of Tr1 cells in these patients have not been directly performed,
490this disorder illustrates the essential role of IL-10 in control-
491ling the intestinal homeostasis [43]. This confirms the
492nonredundancy of both regulatory pathways in the intestine
493and the importance of considering genetic screening in the
494presence of early-onset disease [43]. Indeed, hematopoietic
495stem cell transplantation could be a valid therapeutic option
496for several of not only these disorders but also novel gene
497therapy approaches using CRISPR/Cas9 or other technologies
498could be pursued. However, external factors, like nutrients or
499intestinal microbiota could influence the immune system, con-
500tribute to reduce intestinal inflammation, and induce tolerance
501that provide useful therapeutic insights for the benefit of pa-
502tients with congenital defects [44].
503Main Therapeutic Strategies for CDDs Deriving from
504Dysregulation of Intestinal Immune Response The current
505treatments available for IPEX and IPEX-like syndrome pa-
506tients include supportive therapy, immunosuppressive thera-
507py, and hematopoietic stem cell transplantation (HSCT) [36].
508Positive long-term outcome for IPEX patients can be obtained
509with long term immunosuppressive treatment. However, stud-
510ies demonstrate that immunosuppression does not cure the
511disease and can induce severe side effects, like osteoporosis,
512dyslipidemia secondary to corticosteroids, and also chronic
513renal dysfunction linked to cyclosporine or tacrolimus [45].
514Early HSTC provides the best outcome, before organs are
515damaged by autoimmunity [46]. Gene correction of autolo-
516gous stem cells will hopefully become an option for IPEX
517patients. Other therapeutic approaches, alternative to multiple
518immunosuppression, could also be envisaged, aiming to re-
519establish tolerance in a FOXP3-independent manner. For ex-
520ample, IPEX patient cells can secrete IL-10 and IL-10-
521dependent type 1 T regulatory (Tr1) cells, playing important
522role in peripheral regulation, which can be differentiated de-
523spite the presence of FOXP3mut. Interestingly, patients with
524FOXP3 mutations and late onset or unusual clinical presenta-
525tion are frequently reported. Patients present nephritic-range
526proteinuria, microscopic hematuria and renal insufficiency.
527Renal biopsy demonstrates proliferative glomerulonephritis
528with immune complex deposition [47]. Whether this different
529phenotype is due to the presence of residual protein function
530or to the presence in some patients of more efficient FOXP3-
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531 independent compensatory mechanisms of tolerance remains
532 to be clarified.
533 Considerations on the Diagnostic Approach
534 and Molecular Analysis for CDD Patients
535 Diarrhea is relatively rare in the first weeks of life, but its early
536 onset may be predictive of CDDs and requires hospitalization
537 for an accurate diagnostic work up and therapeutic manage-
538 ment. Early diagnosis is of paramount importance for the out-
539 come of most CDDs. The diagnostic approach to CDDs is a
540 multistep process based on different tools that include anam-
541 nestic and clinical data, laboratory and instrumental diagnostic
542 tools, and pathology and molecular analysis. However, con-
543 sidering the complexity of the CDDs, many cases could have
544 an atypical presentation that limited the application of a sys-
545 tematic approach. Positive familiar history of early-onset
546 chronic diarrhea, polyhydramnios, and/or dilated bowel loops
547 at ultrasound examination during pregnancy is highly sugges-
548 tive of CDDs. In the vast majority of cases, the main clinical
549 manifestation is chronic diarrhea [1••]. In the approach to a
550 newborn or infant with suspected CDD, it is important to
551 remember that also at this particular age, infections and food
552 allergy are frequent causes of chronic diarrhea [48] and that
553 these conditions together with malformations of gastrointesti-
554 nal tract should be considered as primary hypothesis. In the
555 last 10 years, many genes responsible for most CDDs have
556 been identified (Table 1). The availability of DNA sequencing
557 techniques has greatly ameliorated the diagnostic approach to
558 these diseases. Molecular genetics has become helpful to ob-
559 tain early and unequivocal diagnoses, allowing a rapid and
560 targeted therapeutic strategies (Table 2) and reducing repeti-
561 tive invasive and expensive procedures [1••]. Moreover, the
562 identification of disease-causing mutations in the affected
563proband can help to reveal asymptomatic carriers and to offer
564counseling and future prenatal diagnosis [49].
565Whether the type of mutation(s) can help about the severity
566of the clinical phenotype is still under discussion. In specific
567CDDs, such as congenital chloride diarrhea, the clinical ex-
568pression is poorly related to the genotype and the presence of
569modifier genes might contribute to modulate the phenotype.
570However, genotype might predict response to therapy. In fact,
571it has been demonstrated that specific SLC26A3 mutations
572that retain at least some activity of the protein could predict
573a more remarkable effect of oral butyrate therapy [50]. More
574complex in vitro functional studies are needed to explain the
575effect of mutations of uncertain clinical significance, but such
576studies are rarely performed in a routine setting.
577Conclusions
578In recent years, much progress has been made on the
579understanding of the pathogenesis of these conditions,
580thanks to the development of 3D models derived from
581human stem cells, providing a new research perspective
582[1••]. The molecular diagnosis has further changed the
583scenario of the CDDs, opening the way for new therapeu-
584tic strategies such as the transplantation of hematopoietic
585stem cells [1••] and gene therapy endo-nucleases, includ-
586ing Talens or CRISPR/Cas9 [1••]. Long-term studies are
587necessary to provide other information about the progno-
588sis of these conditions. Given the number of the CDDs,
589the complexity of the genotype–phenotype relationship
590and the need for a multidisciplinary counseling for family
591members are essential close collaboration between clinical
592and laboratory as part of an international network. Some
593examples are the Registry of patients with MVID [1••],
594the website Diarrheal Congenital Disorders [1••], and the
t2:1 Table 2 Main therapeutic
strategies for congenital diarrheal
disorders
t2:2 Defects in absorption and transport of
nutrients and electrolytes
• Exclusion diet
• Substitutive therapy
• Parenteral nutrition
t2:3 Defects in enterocyte structure • Total parenteral nutrition
• Antisecretory drugs
• Intestinal transplantation
t2:4 Defects in enteroendocrine cell
differentiation
• Total parenteral nutrition
• Hormone therapy
• Intestinal transplantation
t2:5 Defects in intestinal immune-related
homeostasis
• Total parenteral nutrition
• Hormone therapy
• Immunosuppressive, immunomodulator drugs, biologics
(corticosteroids, cyclosporine, azathioprine, 6-mercaptopurine,
tacrolimus mycophenolate mofetil, sirolimus, infliximab,
rituximab)
• Bone marrow transplantation
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595 consortium IPEX syndrome [1••], in order to provide
596 quick access to analysis and other molecular diagnostic
597 procedures for patients suspected of CDDs.
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